New research suggests that people who discontinue new slimming jabs like Wegovy and Mounjaro can put back on shed pounds far faster than those who stop conventional lifestyle plans.
Research printed in a prominent health publication points out that while overweight people often shed about a fifth of their body weight while undergoing treatment, the weight comes back at an estimated rate of 0.8 kg per month after stopping.
"Users using these drugs need to be informed of the potential of rapid weight regain when the therapy concludes," warns researcher Dr. Susan Jebb.
Such speed of regain suggests a return to original weight within about 18 months.
Analyzing Therapies
The study, which examined 37 of trials involving thousands of patients, compared the results of GLP-1 agonists with conventional dieting.
The team emphasize that people who shed pounds through dieting generally see a more gradual creep back—approximately 100 grams monthly—after stopping.
Understanding the Fast Regain
Experts propose the mode of action of the injections accounts for the amplified regain.
The injections copy a body's own chemical called GLP-1, which moderates hunger.
"Artificially providing GLP-1 levels far above than the body's typical production might result in the body to produce less of its own natural hormone, and could reduce sensitivity to its effects," noted Dr. Adam Collins, a dietetics expert.
"Discontinuation of this hormone supplement results in hunger is no longer kept in check, making binge eating much more probable."
A Lifelong Disease?
Health authorities advise the jabs for people with weight-linked health risks, accompanied by recommended diet and exercise modifications.
Many experts argue that, due to the significant potential of relapse, the treatment might need to be ongoing.
This view is echoed by drug manufacturers, who note that the results "highlight the chronic character of obesity," akin to managing diseases like hypertension.
User Experiences
Individuals who have discontinued the jabs report a sudden resurgence of hunger.
"It was like a trigger activating and you become extremely hungry," said an individual.
This challenge is compounded if patients have not established lasting dietary or behavioural modifications during treatment.
Growing Interest
Survey data indicate that millions of people in the UK have used these injections in the past year, with interest continuing to grow.
- Adoption is higher among women than males.
- The middle-aged demographic shows the greatest usage rates.
- Many access the medications through private healthcare rather than the NHS.
In conclusion, experts stress that while GLP-1 drugs are effective tools for weight loss, they are not a permanent cure and maintained weight loss hinges on integrated behavioural management.